Suzhou Pharmaceutical Technology Co.,Ltd FDA Warning (2017)
Compiled by the Supplement Safety Data Team | Sourced from Official FDA Records on January 06, 2017
Executive Summary
The FDA issued a warning letter to Suzhou Pharmaceutical Technology Co.,Ltd on January 06, 2017 citing cgmp violations. The letter was issued by Center for Drug Evaluation and Research.
Detailed Analysis
False Claims and Regulatory Violations
The FDA identified regulatory violations in Suzhou Pharmaceutical Technology Co.,Ltd's operations or product claims.
Potential Health Risks
Department of Health and Human Services
Regulatory Context
a plan to establish, document, and implement an effective system for managing quality, including written procedures for CGMP related activities and the personnel responsible for oversight
corrective actions for establishing and maintaining adequate storage conditions
Key Entities Identified
Frequently Asked Questions
- What did the FDA find wrong with Suzhou Pharmaceutical Technology Co.,Ltd?
- The FDA issued a warning letter citing cgmp violations related to their products or manufacturing practices.
- Are Suzhou Pharmaceutical Technology Co.,Ltd products safe to use?
- Based on the FDA's findings, consumers should exercise caution. The company was found to have cgmp violations that may affect product safety.
- What should I do if I've used Suzhou Pharmaceutical Technology Co.,Ltd products?
- If you have used products from Suzhou Pharmaceutical Technology Co.,Ltd and experience any adverse effects, contact your healthcare provider immediately. You can also report adverse events to the FDA's MedWatch program.
Source Document
This report is based on an official FDA warning letter. The original document is a public record.
View Original FDA Warning Letter